1. Home
  2. ALTO vs VCRE Comparison

ALTO vs VCRE Comparison

Compare ALTO & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alto Ingredients Inc.

ALTO

Alto Ingredients Inc.

N/A

Current Price

$3.62

Market Cap

282.7M

Sector

Industrials

ML Signal

N/A

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$11.04

Market Cap

271.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ALTO
VCRE
Founded
2003
2000
Country
United States
Sweden
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
282.7M
271.7M
IPO Year
2005
2026

Fundamental Metrics

Financial Performance
Metric
ALTO
VCRE
Price
$3.62
$11.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$8.33
★ $24.48
AVG Volume (30 Days)
★ 1.0M
17.4K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 119.51
N/A
EPS
★ 0.36
N/A
Revenue
★ $917,927,000.00
N/A
Revenue This Year
$5.33
$38.94
Revenue Next Year
$1.09
$694.23
P/E Ratio
$10.31
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.87
$7.88
52 Week High
$6.11
$14.01

Technical Indicators

Market Signals
Indicator
ALTO
VCRE
Relative Strength Index (RSI) 45.38 53.11
Support Level $3.46 $8.83
Resistance Level $3.79 $11.88
Average True Range (ATR) 0.17 0.44
MACD 0.02 0.16
Stochastic Oscillator 33.01 58.65

Price Performance

Historical Comparison
ALTO
VCRE

About ALTO Alto Ingredients Inc.

Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: